DOI:
10.1055/s-00000129
Kardiologie up2date
LinksClose Window
References
Novo Nordisk Worldwide.
Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial.
Im Internet:
http://www.novonordisk.com/media/news-details.2007805.html Stand: 6.5.2016
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.